HealthLeaders Media May 16, 2022
Laura Beerman

One Michigan plan is bringing predictive power to patient drug treatment.

As the social determinants of health grab healthcare’s spotlight, the genetic determinants of health provide precision medicine benefits that one health plan is banking on.

Blue Care Network, a subsidiary of Blue Cross Blue Shield of Michigan (BCBS-MI), has launched Blue Cross Personalized Medicine, the state’s first pharmacogenomics (PGx) program. PGx is a subset of genomics that uses genetic testing to help predict an individual patient’s response to specific drug therapies.

“Our first priority with the Blue Cross Personalized Medicine program is to ensure that a physician is able to provide the right medication, at the right dose, as early in the process as possible,” stated a BCBS-MI press...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Equity/SDOH, Healthcare System, Insurance, Patient / Consumer, Payer, Pharma / Biotech, Precision Medicine, Provider
How Payers are Using AI to Deny Claims and Dent Provider Revenue
Seniors deserve timely access to care, not bureaucratic hurdles | Viewpoint
Fixing the Growing Payer-Provider Divide in Behavioral Health
Cityblock Health Validates Value-Based Care Arrangement with 11.5% Payer Expense Reduction
The best changes 5 payer executives made in 2024

Share This Article